ACTINOGEN MEDICAL LIMITED overview

Actinogen announces peer-reviewed clinical pharmacology manuscript for Xanamem (emestedastat) published in Clinical Pharmacology in Drug Development journal PR Newswire SYDNEY, Feb. 12, 2025 Confirms the utility of the 10 mg daily oral dose of Xanamem being studied in late-stage clinical trials in Alzheimer's disease and major depressive disorder SYDNEY , Feb. 12, 2025 /PRNewswire/ -- Actinogen Medical Limited (ASX: ACW) announces that the publication of its most recent peer-reviewed journal...

Actinogen announces new and unique nonproprietary name of 'emestedastat' for Xanamem PR Newswire SYDNEY, Feb. 5, 2025 Late-stage Alzheimer's trial opens 10 new sites in USA, with results due in 2025 and 2026 SYDNEY , Feb. 5, 2025 /PRNewswire/ -- Actinogen Medical Limited (ASX: ACW) announces that the World Health Organization (WHO) has granted the nonproprietary name of 'emestedastat' to Actinogen for its Xanamem ® /UE2343 once-a-day small molecule in accordance with the WHO's Procedure for the...

Actinogen Medical is an ASX-listed Australian biotech developing its lead asset, emestedastat (Xanamem), a specific and ......

Actinogen randomizes first US participant in XanaMIA phase 2b/3 Alzheimer's disease trial PR Newswire SYDNEY, Dec. 9, 2024 Late-stage trial in Alzheimer's opens 10 sites in US, with results due in 2025 and 2026 Appoints US-based Chief Commercial Officer, Andrew Udell Xanamem's unique ability to control brain cortisol draws widespread coverage in the Australian media. SYDNEY , Dec. 9, 2024 /PRNewswire/ -- Actinogen Medical Limited (ASX: ACW) announces that the first participant was randomized and...

Actinogen announces further positive results on depression in the XanCIDD phase 2a trial PR Newswire SYDNEY, Aug. 26, 2024 Durable benefits previously reported for the MADRS depression scale are supported by the patient-reported outcome of PGI-S and new MADRS responder analyses that underscore benefit at week 10 with a 50% higher rate of remission of depression SYDNEY , Aug. 26, 2024 /PRNewswire/ -- Actinogen Medical ASX: ACW ("ACW" or "the Company") announces that on-going analysis of the...

Actinogen announces achievement of clinically and statistically significant superiority of Xanamem® over placebo on depression in XanaCIDD phase 2a trial PR Newswire SYDNEY, Aug. 12, 2024 There was a clinically meaningful and persistent improvement depression measured by the key secondary endpoint of MADRS. [1] The primary endpoint of superiority to placebo in a cognitive "attention composite" of three Cogstate computerized tests was not met with large improvements seen in both Xanamem and...

Positive Xanamem® biomarker trial published in the Journal of Alzheimer's Disease demonstrating potential Xanamem efficacy in patients with elevated blood pTau PR Newswire SYDNEY, June 26, 2024 The prospectively defined, double-blind analysis of biomarker-positive patients with mild Alzheimer's disease showed more rapid clinical progression in biomarker-positive patients, highlighting the suitability of elevated pTau for selecting patients in the on-going XanaMIA phase 2b trial SYDNEY , June...

Enrolment completed in Actinogen's XanaCIDD phase 2a cognition & depression trial PR Newswire SYDNEY, April 22, 2024 Trial results anticipated in early Q3 this year SYDNEY , April 22, 2024 /PRNewswire/ -- Actinogen Medical Limited (ASX: ACW) announces the full enrolment of 167 participants in the Company's XanaCIDD phase 2a clinical trial in patients with cognitive impairment in major depressive disorder (MDD). The XanaCIDD trial is a proof-of-concept, placebo-controlled, parallel group trial...